Persistence of Biological Treatment and Inhibitors of Jak Kinases in Patients With Rheumatoid Arthritis.
Recruiting · NCT05062421 · Observational (researchers observe without assigning treatment) · Lead sponsor: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
View the official record on ClinicalTrials.gov →What this trial is about
One-center observational study aimed at determining the survival of patients with rheumatoid arthritis treated with targeted synthetic disease-modifying drugs (FAMEsd) and biologic disease-modifying drugs (FAMEb). These patients will be administered a series of medications and a follow-up will be carried out to analyze their evolution.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Patients aged ≥18 years.
- With a diagnosis of Adult Rheumatoid Arthritis according to the 2010 ACR / EULAR criteria.
- Who have received at least one of the doses of the study drugs.
- In follow-up in the consultations of the UGC of Rheumatology of the HUVM.
- With at least two complete evaluations (baseline and final) of clinical variables.
Exclusion criteria
- Patients where the medical records lack sufficient baseline and final variables to perform the analysis.
- Patients in whom more than 50% of the variables to be collected are missing in the data collection.
Where it is running
1 location listed.
- Hospital Universitario Virgen macarena - Seville, Spain